comprehensive -WSS

comprehensive

author：explore 2025-08-22 15:48:36 - browse：3

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： NIH documents show early flaws of $1.6 billion long Covid program

leisure time

WSS

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

BMI, flaws aside, is found to be useful estimate of body fat in youth

With trial win, GSK could get blood cancer drug back on market

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

The new shift in health care is toward less care

A clever new way to fix Medicaid and graduate medical education

focus

comprehensive

explore

Peter Hotez and the public health issue of online harassment

Free speech concerns arise in wake of journal editor Eisen's firing

What does generative AI mean for health care? We asked experts

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Medical records are filled with copy

Senate panel clears PBM, hopsital reforms

The cancer drug shortage isn’t new — and neither are the solutions

Medicare solvency divides Republicans at the presidential debate

State Dept. review finds Biden bears some blame for Afghanistan failures

At ASCO, AstraZeneca reports strong data for breast cancer drug

hotspot

Sanofi CEO defends move to abandon profit guidance, boost research

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

How to increase colonoscopy rates? Looks like an AI can help

Woman returns to dialysis after doctors remove transplanted pig kidney

HPV cancer vaccine study demonstrates efficacy

Woman returns to dialysis after doctors remove transplanted pig kidney

hotspot

focus

leisure time

hotspot